Eposin 100 mg/5 ml (IV Infusion)
100 mg vial: ৳ 560.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Etoposide |
| Company | Pharmachemie bv |
Indications
- Management of Small Cell Lung Cancer
- First-line treatment in patients with small cell lung cancer
Pharmacology
- Pharmacotherapeutic classification: podophyllotoxin derivatives
- Inhibition of mitosis by blocking microtubular assembly
- Inhibition of cell cycle progression at a premitotic phase
- Biphasic disposition with distribution half-life of about 1.5 hours
- Total body clearance values range from 33 to 48 ml/min or 16 to 36 ml/min/m 2
- Linear increase of AUC and Cmax values with dose
- Mean volumes of distribution at steady state fall in the range of 18 to 29 liters or 7 to 17 L/m 2
Dosage & Administration
- Dosing range for small cell lung cancer in combination with other drugs
- Initial dose modification based on measured creatinine clearance
- Subsequent dosing based on patient tolerance and clinical effect
Interaction
- Interaction with high-dose cyclosporine a
- Recommendation for periodic complete blood counts during treatment
Contraindications
- Contraindicated in patients with previous hypersensitivity to Etoposide or any component of the formulation
Side Effects
- Dose-related myelosuppression
- Granulocyte and platelet nadirs occurring 7 to 16 days after drug administration
- Nausea, vomiting, mucositis, and esophagitis as gastrointestinal toxicities
- Transient hypotension following rapid intravenous administration
- Anaphylactic-like reactions characterized by chills, fever, tachycardia, bronchospasm, dyspnea, and/or hypotension
- Reversible alopecia, rash, urticaria, and pruritus
- Other infrequent adverse reactions including abdominal pain, constipation, dysphagia, fatigue, malaise, transient cortical blindness, optic neuritis, and fever
Pregnancy & Lactation
- Pregnancy category D
- Etoposide found in human milk
- Patients receiving Etoposide should not breastfeed
Precautions & Warnings
- Frequent observation for myelosuppression
- Dose limiting bone marrow suppression
- Necessary studies to be obtained at the start of therapy and prior to each subsequent cycle of Eposin
- Occurrence of a platelet count below 50,000/mm 3 or an absolute neutrophil count below 500/mm 3 as an indication to withhold further therapy
- Possible occurrence of anaphylactic reaction
- Higher rates of anaphylactic-like reactions reported in children who received infusions at higher concentrations
- Reinstitute Eposin therapy with caution
- Increased risk for Eposin associated toxicities in patients with low serum albumin
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Must be stored under refrigeration 2°C-8°C
- Capsules are stable for 24 months under refrigeration conditions
- Keep all medicines out of reach of children
- Protect from light
- Proper handling and disposal of anticancer drugs should be considered